Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice

Procedia in Vaccinology

Volumn 1, Issue 1, 2009, Pages 15-22

  Moise, Lenny ^a,b   Ardito, Matt ^a   Desrosiers, Joe ^a   Schriewer, Jill ^c   Buller, Mark ^d   Frey, Sharon E ^d   Gregory, Stephen H ^b,e   Moss, Steven F ^b,d   Lee, Jinhee ^e   Kornfeld, Hardy ^e,f   Martin, Bill ^a   De Groot, Anne S ^a,b,c  

^a EpiVax   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

epitope; Immunome; Smallpox: helicobacter; T cell; Tularemia; vaccine

Indexed keywords

ANTIGEN; BCG VACCINE; DNA VACCINE; DRUG VEHICLE; EPITOPE; HELICOBACTER PYLORI VACCINE; HELICOVAX; HLA ANTIGEN CLASS 2; IMMUNOME DERIVED EPITOPE DRIVEN VACCINE; LIPOSOME; LIVE VACCINE; PROTEIN P27; SMALLPOX VACCINE; TULAREMIA VACCINE; TULIVAX; UNCLASSIFIED DRUG; VACCINIA VACCINE; VENNVAX;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SMALLPOX; T LYMPHOCYTE; TUBERCULOSIS; TULAREMIA; VACCINIA; VIRUS INFECTION;

EID: 71549129281     PISSN: 1877282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.provac.2009.07.004     Document Type: Article

References (60)

1. Martin, W, Ardito M, Tassone R., Desrosiers J., Knopf, P. McMurry JA, Moise L., De Groot AS. Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-driven Vaccines. For book entitled, Development of Vaccines: From Discovery to Clinical Testing. Editors Indrish Srivastava and Manmohan Singh Publisher: John Wiley and Sons.
2. De Groot A.S., Bosma A., Chinai N., Frost J., Jesdale B.M., Gonzalez B.M., Martin W., and Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19 (2001) 4385-4395
3. Mathurin K.S., Martens G.W., Kornfeld H., and Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol. 83 8 (2009) 3528-3539
4. Chen HW, Zhang Z, Huber E, Chao CC, Wang H, Dasch GA, Ching WM. Identification of cross-reactive epitopes on the conserved 47 kDa antigen of Orientia tsutsugamushi and human serine protease. Infect Immun. 2009 Mar 16. (Epub).
5. Mathurin K.S., Martens G.W., Kornfeld H., and Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol. 83 8 (2009) 3528-3539 Epub 2009 Feb 4
6. P Welsh R.M., and Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol. 5 7 (2007) 555-563 Review
7. Grant S.F., and Hakonarson H. Genome-wide association studies in type 1 diabetes. Curr Diab Rep. 9 2 (2009) 157-163
8. Aarnisalo J., Veijola R., Vainionpää R., Simell O., Knip M., and Ilonen J. Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes. Diabetologia. 51 5 (2008) 769-772 Epub 2008 Feb 16
9. Markovic-Plese S., Hemmer B., Zhao Y., Simon R., Pinilla C., and Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol. 169 1-2 (2005) 31-38 Epub 2005 Sep 15
10. Blattman J.N., Sourdive D.J., Murali-Krishna K., Ahmed R., and Altman J.D. Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection. J Immunol. 165 11 (2000 Dec 1) 6081-6090
11. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., Elbeik T., Feinberg M.B., Buchbinder S.P., and Walker B.D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 156 7 (1996 Apr 1) 2616-2623
12. Doolan D.L., Wizel B., and Hoffman S.L. Class I HLA-restricted cytotoxic T lymphocyte responses against malaria- elucidation on the basis of HLA peptide binding motifs. Immunol Res. 15 4 (1996) 280-305 Review
13. Gianfrani C., Oseroff C., Sidney J., Chesnut R.W., and Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 61 (2000) 438-452
14. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 74 (2000) 8140-8150
15. Kong W.P., Wu L., Wallstrom T.C., Fischer W., Yang Z.Y., Ko S.Y., Letvin N.L., Haynes B.F., Hahn B.H., Korber B., and Nabel G.J. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol. 83 5 (2009) 2201-2215 Epub 2008 Dec 24
16. Ramduth D., Day C.L., Thobakgale C.F., Mkhwanazi N.P., de Pierres C., Reddy S., van der Stok M., Mncube Z., Nair K., Moodley E.S., Kaufmann D.E., Streeck H., Coovadia H.M., Kiepiela P., Goulder P.J., and Walker B.D. Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS ONE. 4 4 (2009) e5013 Epub 2009 Apr 7
17. Blattman J.N., Sourdive D.J., Murali-Krishna K., Ahmed R., and Altman J.D. Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection. J Immunol. 165 1 1 (2000) 6081-6090
18. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., Sissons P., Rowland-Jones S., Bell J.I., and Moss P.A. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 74 17 (2000) 8140-8150
19. Gianfrani C., Oseroff C., Sidney J., Chesnut R.W., and Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol. 61 5 (2000) 438-452
20. Ahlers J.D., Belyakov I.M., Thomas E.K., and Berzofsky J.A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest. 108 (2001) 1677-1685
21. De Groot A.S., Sbai H., Saint-Aubin C., McMurry J.A., and Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell. Biol. 80 (2002) 255-269
22. Inaba H., Martin W., De Groot A.S., Qin S., and De Groot L.J. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J Clin Endocrinol Metab. 91 (2006) 2286-2294
23. De Groot A.S., Jesdale B.M., Szu E., Schafer J.R., Chicz R.M., and Deocampo G. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retroviruses. 13 (1997) 529-531
24. Bond K.B., Sriwanthana B., Hodge T.W., De Groot A.S., Mastro T.D., Young N.L., Promadej N., Altman J.D., Limpakarnjanarat K., and McNicholl J.M. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses. 20 (2001) 703-717
25. McMurry J., Sbai H., Gennaro M.L., Carter E.J., Martin W., and De Groot A.S. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb). 85 (2005) 95-105
26. Dong Y., Demaria S., Sun X., Santori F.R., Jesdale B.M., De Groot A.S., Rom W.N., and Bushkin Y. HLA-A2-restricted CD8+-cytotoxic- T cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun. 72 (2004) 2412-2415
27. Koita O.A., Dabitao D., Mahamadou I., Tall M., Dao S., Tounkara A., Guiteye H., Noumsi C., Thiero O., Kone M., Rivera D., McMurry J.A., Martin W., and De Groot A.S. Confirmation of immunogenic consensus sequence HIV-1 T cell epitopes in Bamako, Mali and Providence. Rhode Island. Hum Vaccin. 2 3 (2006) 119-128
28. De Groot A.S. Immunomics: Discovering New Targets for Vaccine and Therapeutics. Drug Discovery Today. 11 (2006) 203-209
29. Jesdale BM, Deocampo G, Meisell J, Mullen L, Beall J, Marinello M, A.S. De Groot, Matrix-based prediction of MHC-binding peptides: the Epimatrix algorithm, reagent for HIV research, Vaccines 97, pp. 57-64, Cold Spring Harbor Laboratory Press 1997.
30. De Groot A.S., Bosma A., Chinai N., Frost J., Jesdale B.M., Gonzalez M.A., Martin W., and Saint-Aubin C. From genome to vaccine: In silico predictions, ex vivo verification. Vaccine 19 31 (2001 Aug 14) 4385-4395
31. Wang P., Sidney J., Dow C., Mothé B., Sette A., and Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 4 4 (2008 Apr 4) e 1000048
32. Peters B., Sidney J., Bourne P., Bui H.H., Buus S., Doh G., Fleri W., Kronenberg M., Kubo R., Lund O., Nemazee D., Ponomarenko J.V., Sathiamurthy M., choenberger S., Stewart S., Surko S., Way P., Wilson S., and Sette S.A. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol. 3 3 (2005) e91
33. Zhang Q, Wang P, Kim Y, Haste-Andersen P, Beaver J, Bourne PE, Bui HH, Buus S, Frankild S, Greenbaum J, Lund O, Lundegaard C, Nielsen M, Ponomarenko J, Sette A, Zhu Z, Peters B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W513-8.
34. De Groot A.S., and Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 131 2 (2009) 189-201
35. Koren E., De Groot A.S., Jawa V., et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124 1 (2007) 26-32
36. De Groot A.S., and Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 10 3 (2007) 332-340
37. De Groot A.S., and Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 28 11 (2007) 482-490
38. De Groot A.S., P. M. Knopf, D. Rivera and W. Martin. Immunoinformatics applied to modifying and improving biological therapeutics. Kluwer publications Immunoinformatics. Series: Immunomics Reviews: Vol. 1. Schönbach, Christian; Ranganathan, Shoba; Brusic, Vladimir (Eds.) 2007, ISBN: 978-0-387-72967-1. Available: September 21, 2007.
39. Thurmond J., Yoon H., Kuiken C., et al. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24 14 (2008) 1639-1640
40. De Groot A.S., Jesdale B.M., Szu E., et al. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res Hum Retroviruses 13 (1997) 529-531
41. Bond K.B., Sriwanthana B., Hodge T.W., et al. An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses 20 (2001) 703-717
42. McMurry J., Sbai H., Gennaro M.L., et al. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis 85 (2005) 95-105
43. Dong Y., Demaria S., Sun X., et al. HLA-A2-restricted CD8+-cytotoxic- T cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun 72 (2004) 2412-2415
44. Tatarewicz S.M., Wei X., Gupta S., et al. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27 6 (2007) 620-627
45. McMurry J.A., Moise L., Gregory S.H., and De Groot A.S. Tularemia vaccines - an overview. Med Health R I. 90 10 (2007) 311-314
46. Smith C.L., Mirza F., Pasquetto V., Tscharke D.C., Palmowski M.J., Dunbar P.R., Sette A., Harris A.L., and Cerundolo V. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175 12 (2005 Dec 15) 8431-8437
47. Jing L, Davies DH, Chong TM, Chun S, McClurkan CL, Huang J, Story BT, Molina DM, Hirst S, Felgner PL, Koelle DM. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol. 2008 Jul;82(14):7120-34. Epub 2008 May 14. Erratum in: J Virol. 2009 Mar;83(5):2404.
48. Kuzushita N., Rogers A.B., Monti N.A., Whary M.T., Park M.J., Aswad B.I., Shirin H., Koff A., Eguchi H., and Moss S.F. p27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice. Gastroenterology 129 5 (2005) 1544-1556
49. Eliott S.L., Suhrbier A., Miles J.J., Lawrence G., Pye S.J., Le T.T., Rosenstengel A., Nguyen T., Allworth A., Burrows S.R., Cox J., Pye D., Moss D.J., and Bharadwaj M. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82 3 (2008) 1448-1457 Epub 2007 Nov 21
50. McKinney D.M., Skvoretz R., Livingston B.D., Wilson C.C., Anders M., Chesnut R.W., Sette A., Essex M., Novitsky V., and Newman M.J. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 173 3 (2004 Aug 1) 1941-1950
51. Wilson C.C., Newman M.J., Livingston B.D., MaWhinney S., Forster J.E., Scott J., Schooley R.T., and Benson C.A. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15 6 (2008) 986-994
52. De Groot A.S., Rivera D.A., McMurry J.A., Buus S., and Martin W. Identification of Immunogenic HLA-B7 "Achilles' heel" Epitopes Within Highly Conserved Regions of HIV. Vaccine 26 (2008) 3059-3071
53. De Groot AS, McMurry JA, Moise L, Martin W. Epitope-based Immunome-derived Vaccines: A Strategy for Improved Design and Safety. Springer Immunomics Series. Editor Andras Falus. Falus, Andras (Ed.) 2009.
54. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., and Casimiro D.R. Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 9653 (2008 Nov 29) 1894-1905 Epub 2008 Nov 13
55. Wilson C.C., Newman M.J., Livingston B.D., MaWhinney S., Forster J.E., Scott J., Schooley R.T., and Benson C.A. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15 6 (2008) 986-994 Epub 2008 Apr 9
56. Hanke T. STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Rev Vaccines 7 3 (2008) 303-309
57. Moutaftsi M., Peters B., Pasquetto V., Tscharke D.C., Sidney J., Bui H.H., Grey H., and Sette A. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24 7 (2006) 817-819
58. Moise L., and De Groot A.S. Putting immunoinformatics to the test. Nat Biotechnol. 24 7 (2006) 791-792
59. Sette A., and Sidney J. Nine major HLA Class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 50 3-4 (1999) 201-212
60. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., and Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 174 12 (2005 Jun 15) 7676-7683